Robert Q Le
Overview
Explore the profile of Robert Q Le including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le R, Przepiorka D, Chen H, Shen Y, Pulte E, Norsworthy K, et al.
Blood
. 2024 May;
144(2):206-215.
PMID: 38728428
Complete remission with partial hematological recovery (CRh) has been used as an efficacy endpoint in clinical trials of nonmyelosuppressive drugs for acute myeloid leukemia (AML). We conducted a pooled analysis...
2.
Le R, Wang X, Zhang H, Li H, Przepiorka D, Vallejo J, et al.
Oncologist
. 2022 Apr;
27(6):493-500.
PMID: 35363318
On September 22, 2021, the Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of one or two lines of systemic therapy...
3.
Przepiorka D, Le R, Ionan A, Li R, Wang Y, Gudi R, et al.
Clin Cancer Res
. 2022 Feb;
28(12):2488-2492.
PMID: 35135839
On July 16, 2021, the FDA approved belumosudil, a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic GvHD (cGvHD) after failure of at least two...
4.
Pollyea D, Barrett J, DiNardo C, Michaelis L, Roboz G, Le R, et al.
Clin Cancer Res
. 2021 Nov;
28(5):816-820.
PMID: 34753779
The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together...
5.
Jain N, Chen M, Shanbhag S, Anandi P, Tian X, Ito S, et al.
Clin Hematol Int
. 2021 Oct;
2(3):109-116.
PMID: 34595451
Long-term allogeneic hematopoietic cell transplant (allo-HCT) survivors suffer an elevated risk of coronary heart disease (CHD). We conducted a prospective, nonrandomized, cross-sectional study to screen asymptomatic survivors at a single...
6.
Le R, Li L, Yuan W, Shord S, Nie L, Habtemariam B, et al.
Oncologist
. 2018 Apr;
23(8):943-947.
PMID: 29622697
Implications For Practice: Severe or life-threatening chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS) requires urgent treatment to prevent fatal outcomes. In two independent cohorts, the majority of...
7.
Gea-Banacloche J, Komanduri K, Carpenter P, Paczesny S, Sarantopoulos S, Young J, et al.
Biol Blood Marrow Transplant
. 2016 Oct;
23(6):870-881.
PMID: 27751936
Immune reconstitution after hematopoietic stem cell transplantation (HCT) beyond 1 year is not completely understood. Many transplant recipients who are free of graft-versus-host disease (GVHD) and not receiving any immunosuppression...
8.
Anand A, Anandi P, Jain N, Lu K, Dunavin N, Hourigan C, et al.
Support Care Cancer
. 2015 Jul;
24(2):815-822.
PMID: 26190358
Objective: The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of oropharyngeal mucositis...
9.
Chokshi P, Anandi P, Jain N, Dunavin N, Le R, Ito S, et al.
Biol Blood Marrow Transplant
. 2015 Feb;
21(5):954-5.
PMID: 25711513
No abstract available.
10.
Jain N, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, et al.
Bone Marrow Transplant
. 2014 Nov;
50(2):189-196.
PMID: 25387087
Although there are now fewer allo-SCTs performed for CML, leukemic relapse post transplant remains a persistent problem. To better define clinical and biological parameters determining postrelapse outcome, we studied 59...